AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02648321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
Study NCT02648321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: General education about healthy lifestyle and diet.
Study NCT01818960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IRA-PCI
Description: IRA only PCI at the time of Primary PCI
Study NCT01818960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SS-PCI
Description: Same sitting multivessel PCI as an adjunct to primary PCI
Study NCT02707809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion
Study NCT02186366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Massage Therapy
Description: Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
Study NCT02186366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
Study NCT04167371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
Study NCT04167371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
Study NCT03280095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-codamol 15mg/500mg capsule
Study NCT03280095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co-codamol 30mg/500mg tablet
Study NCT00908011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: 10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
Study NCT03555539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study NCT03973489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
Study NCT00733512 — intervention group
Intervention type: DEVICE
Intervention: ReSTOR
Description: Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
Study NCT00950690 — intervention group
Intervention type: DRUG
Intervention: Xalatan 0.005% eye drops
Description: ophthalmic solution dosed once daily for 3 months
Study NCT02752867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jianpi Yishen Huatan Granules
Description: Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
Study NCT02752867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the placebo
Description: Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
Study NCT03245671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog Injectable Product
Description: 80 mg of Kenalog will be used.
Study NCT03245671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decadron Phosphate, Injectable
Description: 15 mg of Decadron will be used.
Study NCT03245671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid Injection
Description: Patient will receive epidural steroid injections of either Kenalog or Decadron.
Study NCT03623984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Dotatate
Description: Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
Study NCT03952897 — intervention group
Intervention type: OTHER
Intervention: balneotherapy
Description: 10 days of balneotherapy with immersion techniques using Fitero spa water.
Study NCT04531319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
Study NCT03554538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web app exercises program
Description: Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
Study NCT03554538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Exercise on an evidence based program for shoulder pain
Study NCT02750813 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A contact lenses
Study NCT02433093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 22 days of once-daily oral matching placebo capsules.
Study NCT03101592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-month ART dispensing
Description: Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
Study NCT02750813 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Study NCT04141345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
Study NCT02884791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral carbohydrate challenge
Description: Participants will fast for 8 hours and then drink a beverage containing fructose.
Study NCT02461914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: 200µg,injected subcutaneously,once a week.
Study NCT02461914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 5mg,oral,two times.
Study NCT02889510 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: liraglutide
Description: 7-week subcutaneous liraglutide once daily
Study NCT03101592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six-month ART dispensing
Description: Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
Study NCT04479098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: The exercise training program will last 12 weeks, with a frequency of three sessions per week, held on Mondays, Wednesdays, and Fridays. Each session will last approximately 50 minutes. Whenever the maximum number of pre-established repetitions is successfully performed, the intensity will be increased by 5 to 10%. All sessions will be supervised by trained professionals.
Study NCT04479098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise detraining
Description: The exercise detraining will last 12 weeks without exercise.
Study NCT02311192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography B-scan
Description: The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
Study NCT00792129 — intervention group
Intervention type: DEVICE
Intervention: The Atavi System
Description: The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used.
Study NCT02889510 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: 7-week subcutaneous placebo once daily
Study NCT03229889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cialis 5Mg Tablet
Description: Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
Study NCT03229889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flomax 0.4Mg Capsule
Description: Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
Study NCT03229889 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cialis + Flomax
Description: Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
Study NCT03229889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
Study NCT04567771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete quality of life questionnaires
Study NCT02476630 — intervention group
Intervention type: DEVICE
Intervention: StO2 measurement
Description: All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
Study NCT02476630 — intervention group
Intervention type: OTHER
Intervention: Blood Gases
Description: All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
Study NCT00558324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Mechanical microkeratome Hansatome 160 microns
Study NCT00558324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Mechanical microkeratome K 3000 130 microns
Study NCT00558324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Femtoseconds laser 100 microns
Study NCT00961493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance based behavioral therapy
Description: 16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
Study NCT00961493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied relaxation
Description: 16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
Study NCT02865434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study NCT02946255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
Study NCT02973906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADAPT Self Directed web
Description: In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
Study NCT02973906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADAPT individualized web-facilitated
Description: This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
Study NCT02973906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group-based ADAPT
Description: Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
Study NCT02386761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD)
Study NCT02386761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD)
Study NCT03291145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta Blockers
Description: With and without Beta Blockers
Study NCT03291145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Brisk Standing before and after seven days treatment with Spironolactone
Study NCT03718039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
Study NCT03718039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer Lock applicator
Description: Applicator for instillation.
Study NCT03718039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial access device
Description: Device for withdrawal of drug product.
Study NCT04567771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete adverse event assessments
Study NCT04567771 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo proton or intensity modulated radiation therapy
Study NCT03301415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
Study NCT02393469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
Study NCT02865434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT Imaging (60 Minutes post-injection)
Description: Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
Study NCT02865434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT Imaging (180 Minutes post-injection)
Description: Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
Study NCT02865434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body planar SPECT imaging (15 Minutes post-injection)
Description: Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
Study NCT02865434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body planar SPECT imaging (60 Minutes post-injection)
Description: Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
Study NCT02865434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body planar SPECT imaging (180 Minutes post-injection)
Description: Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
Study NCT02865434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole body planar SPECT imaging (18-20 Hours post-injection)
Description: Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
Study NCT02393469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education and self-management for COPD
Description: Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
Study NCT03247673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P16
Description: CT-P16 is a biosimilar product for Avastin
Study NCT03247673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Avastin
Description: EU-approved Avastin
Study NCT03247673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Avastin
Description: US-licensed Avastin
Study NCT02554838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
Study NCT02554838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
Study NCT02554838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home assessment and modification
Description: Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
Study NCT02865434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection for PK Testing (15 Mins Before Injection)
Description: Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
Study NCT02554838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home assessment and modification
Description: Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
Study NCT02554838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
Study NCT03269786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)
Description: Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
Study NCT03269786 — intervention group
Intervention type: DEVICE
Intervention: biannual ultrasonography
Description: portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes